Literature DB >> 28856102

PJP granuloma in an Immune competent host: Case report and literature review.

Chandra S Pingili1,2, Vel Sivapalan1,2.   

Abstract

PJP (Pneumocystis jirovecii) is a fungal agent by taxonomy. Ones considered a protozoan, it is now recognized as fungi based on ribosomal RNA and other gene sequence homologies, the composition of their cell walls, and structure of key enzymes. This organism generally affects immunocompromised hosts with a CD4 count <200 or <15%.Review of literature does support a rare occurrence of PJP infections in immunocompetent hosts.PJP can occur at normal CD 4 levels.

Entities:  

Keywords:  Non HIV patient; PJP granuloma

Year:  2017        PMID: 28856102      PMCID: PMC5565774          DOI: 10.1016/j.idcr.2017.06.011

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Case report

53 y/o Hispanic woman was diagnosed with stage III left breast Cancer. She is now s/p chemotherapy with Paclitaxel single agent one year ago, radiation and s/p left mastectomy. She had a follow up screening CT chest that suggested new Left upper lobe nodules (LUL). A recent MRI revealed 2 new nodules of the left breast. This prompted the oncologist to get a repeat chest CT .There was new LUL nodule, >1 cm not seen in previous study-last done approximately 9 months prior to current presentation (Fig. 1).These lesions were surprisingly a new finding on the new imaging. The Patient however was asymptomatic. She denied any SOB, cough, fever, night sweats, chills, hemoptysis, weight loss or any other complaints. There was no recent travel or exposure to sick contacts and there is no history of exposure to tuberculosis. Her past medical history is notable only for pulmonary embolism, hypertension and breast cancer.
Fig. 1

XXX.

XXX. On physical exam she was afebrile, blood pressure was 120/76, and pulse of 78 regular, respirations of 18 with 98% oxygen saturations on room air. Her physical examination was unremarkable except for left mastectomy scar with no signs of infection or inflammation. She did not have oral thrush, lymphadenopathy, and rash and there was no visceromegaly. Labs −please see Table 1. CT chest suggested multiple small nodules measuring up to 1.1 cm in the left upper lobe, not seen in previous study (Fig. 1). A PET scan revealed activity of new conglomerate of LUL lung nodules which may represent metastatic disease. Patient underwent Video-assisted thoracoscopic surgery (VATS) with wedge resection of the nodules. Pathological examination shows Well circumscribed fibro-caseous lesions with central core of necrotic material surrounded by palisading rim of epithelioid histiocytes and multinucleated giant cells consistent with necrotizing granulomas. AFB stain and gram stain was negative.Biospy of the nodules were negative for malignancy. Silver methanamine stain was positive for PJP. This was confirmed with immunohistochemistry. Her HIV antibody test was negative and so was her HIV PCR. Her cd 4 count was 648. She was treated with Trimethoprim-sulfamethoxazole DS 2 pills twice a day for 2 weeks. She remained asymptomatic throughout her clinical course.
Table 1

Laboratory information at admission.

WBC3.6143NA
HB12.24.5K
HCT37105CL
PLT29028CO2
PMN4413BUN
LYMPHOCYTES390.7Cr
EOSINOPHILS49.6Ca
LDH10025AST
ALB440ALT
T BILIRUBIN0.771ALK
QuantiferonNegativeNegativePPD
AFB stainNegativeNegativeGram stain
AFB cultureNegative
Laboratory information at admission.

Discussion

PJP is an opportunistic pathogen affecting cellular immunocompromised hosts. It generally affects patients with CD4 count <200 [1]. Pneumocystis is transmitted by the airborne route. Acquisition of new infections in humans is most likely by person-to-person spread. Individuals with normal immune systems may have asymptomatic lung colonization and may serve as a reservoir for spread of Pneumocystis to immunocompromised hosts [2]. PJP has been documented in non HIV hosts too. Patients on long term steroid suppression are at a high risk of developing PJP infections. This group of patients are next in the list after patients with AIDS defining illness [3]. 16–25 mg of prednisolone per day or ≥4 mg dexamethasone daily for ≥4 weeks are at risk [4]. Patients with underlying malignancies receiving chemotherapy and biological agents are at a risk of developing PJP infections if they are not on appropriate prophyalxis.Hematological malignancies lead the list. Allogenic stem cell transplant patients are at a higher risk of PJP infections compared to autologous transplants [4]. Organ transplant patients, patients with underlying immunological or rheumatologial problems receiving immune modulation therapy are also at risk of developing PJP infections if they are not on prophylactic drugs. Polymyositis, dermatomyositis, SLE and vasculopathies all increase the risk of PJP infections when patients are managed with immunosuppressant or immune modulating agents [5], [6], [7], [8]. Patients receiving R-CHOP14 (Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone chemotherapy on a 14-day cycle), FCR (Fludarabine, Cyclophosphamide, Rituximab), AVBD (Adriamycin, vincristine, bleomycin, dexamethasone), Gemcitabine and high-dose methotrexate all at a moderate risk of developing PJP infections. T cell blockers and depleting agents carry the highest risk for PJP infections [4]. Please see Table 2.
Table 2

Definitive and Probable causes of PJP infection.

Patients with AIDS defining illness
Hematological malignancies like ALL,AML,all Allogenic HSCT, all children and selected high risk adults with autologous HSCT, Methotrexate, R-CHOP regimen, Lymphocyte depleting agents (qualitative and quantitative)
use of >16 mg prednisolon e or > = 4 mg dexamethasone for > = 4 weeks
Use of Temozolomide for glioblastoma multiforme
FCR (fludarabine, cyclophosphamide, rituximab)
AVBD (Adriamycin, Vincristine, Bleomycin, Dexamethasone)
Gemcitabine
Polymyositis, Dermatomyositis,SLE and Vasculopathies
Organ transplant patients
Definitive and Probable causes of PJP infection. Fever, dyspnea with oxygen desaturation is the usual presentation. Presentation is more severe in the non HIV group of patients despite having a less biological burden with PJP. Chest x ray usually shows nonspecific infiltrates. Serum LDH is usually elevated. Non HIV individuals have a higher mortality compared to HIV individuals [4], [12]. Diagnosis of PJP is generally based on suspicion from history and physical exam. Respiratory fluids can be stained to recognize the two forms of the organism, trophozoite and cyst forms. Methenamine silver and toluidine blue preparations stain only the cyst wall and do not allow detection of trophozoites. However, Giemsa stains detect all life stages of PJP. Direct and indirect immunofluorescent assays (DFA, IFA) are specific for different life stages; depending on the antibody used. Comparative studies have shown DFA and IFA to be the most sensitive stains for P. jirovecii in sputum and bronchoalveolar lavage, with sensitivities of 97% and 90% respectively. PCR can replace staining studies. A meta-analysis of PCR studies has shown a pooled sensitivity of 99% and specificity of 92% in the non-HIV patient population [4], [9], [10]. However PCR has high negative predictive value and is reserved to rule out infection. QPCR is quantitative PCR assay targeting the mitochondrial large subunit rRNA gene. This has been used to differentiate between active infection and colonizers with variable results but a combined qPCR in the BAL fluid {Broncho alveolar lavage} and Serum (1–3)–D-Glucan greatly enhanced the sensitivity and specificity of the study [11]. Beta-D-glucan is a cell wall component of PJP. Beta-D-glucan assays can be used to diagnose PJP infection given its high sensitivity and specificity. However Beta −D −Glucan can be elevated with invasive Aspergillosis, Candidiasis, Hemodialysis with cellulose membranes, intravenous immunoglobulin, albumin, gauze packing of serosal surfaces, Intravenous amoxicillin-clavulanic acid, Piperacillin tazobactam and infections with certain bacteria that contain cellular beta-glucans, such as Pseudomonas aeruginosa [12], [13]. Trimethoprim-sulfamethoxazole (BACTRIM) combined with steroids in a severe and moderate to severe case is the drug of choice. Bactrim also is the drug of choice for prevention. For patients with sulfonamide allergy, Atovaquone, Dapsone and Pentamidine offer suitable alternative prophylactic regimens. Dapsone is also a sulfonamides derivative and is contraindicated in patients with severe sulfa allergy and in patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Granulomatous PJP is a very rare presentation. Approximately 16 cases have been reported among patients with malignancy. Commonly reported as solitary or up to 3 nodules. Most of them were either on steroids or had underlying hematological malignancies and were on chemotherapy [14], [15], [16], [17].

Conclusion

PJP granulomatous lesions are very rare clinical presentations. Normal human lung can act as a reservoir with colonization for PJP.When the cellular immune system is depressed, PJP can manifest as a full blown illness or a walled off granuloma as here.
  16 in total

Review 1.  Non-culture-based diagnostics for opportunistic fungi.

Authors:  Monique A S H Mennink-Kersten; Paul E Verweij
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

2.  Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity.

Authors:  Monique A S H Mennink-Kersten; Dorien Ruegebrink; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 3.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

Authors:  Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2002-03-21       Impact factor: 9.079

4.  Pneumocystis jirovecii genotypes and granulomatous pneumocystosis.

Authors:  A Totet; H Duwat; G Daste; A Berry; R Escamilla; G Nevez
Journal:  Med Mal Infect       Date:  2006-03-31       Impact factor: 2.152

5.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01

Review 6.  Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies.

Authors:  Sadatomo Tasaka; Hitoshi Tokuda
Journal:  J Infect Chemother       Date:  2012-08-06       Impact factor: 2.211

7.  Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population.

Authors:  Carolina A Ponce; Myriam Gallo; Rebeca Bustamante; Sergio L Vargas
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Serum indicators for the diagnosis of pneumocystis pneumonia.

Authors:  Sadatomo Tasaka; Naoki Hasegawa; Seiki Kobayashi; Wakako Yamada; Tomoyasu Nishimura; Tsutomu Takeuchi; Akitoshi Ishizaka
Journal:  Chest       Date:  2007-04       Impact factor: 9.410

9.  Single nodular opacity of granulomatous pneumocystis jirovecii pneumonia in an asymptomatic lymphoma patient.

Authors:  Hyun Soo Kim; Kyung Eun Shin; Ju-Hie Lee
Journal:  Korean J Radiol       Date:  2015-02-27       Impact factor: 3.500

10.  Granulomatous PJP presenting as a solitary lung nodule in an immune competent female.

Authors:  J Lam; M M Kelly; R Leigh; M D Parkins
Journal:  Respir Med Case Rep       Date:  2013-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.